Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma

Bone Marrow Transplantation volume 51, pages 1032–1040 (2016)Cite this article

Subjects

Abstract

Multiple myeloma (MM) is the leading indication for autologous stem cell transplantation (ASCT) worldwide. The safety and efficacy of reducing hospital stay for MM patients undergoing ASCT have been widely explored, and different outpatient models have been proposed. However, there is no agreement on the criteria for selecting patients eligible for this strategy as well as the standards for their clinical management. On the basis of this rationale, the Italian Group for Stem Cell Transplantation (GITMO) endorsed a project to develop guidelines for the management of outpatient ASCT in MM, using evidence-based knowledge and consensus-formation techniques. An expert panel convened to discuss the currently available data on the practice of outpatient ASCT management and formulated recommendations according to the supporting evidence. Evidence gaps were filled with consensus-based statements. Three main topics were addressed: (1) the identification of criteria for selecting MM patients eligible for outpatient ASCT management; (2) the definition of standard procedures for performing outpatient ASCT (model, supportive care and monitoring during the aplastic phase); (3) the definition of the standard criteria and procedures for re-hospitalization during the aplastic phase at home. Herein, we report the summary and the results of the discussion and the consensus.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Costa LJ, Zhang MJ, Zhong X, Dispenzieri A, Lonial S, Krishnan A et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 1615–1624.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant 2015; 50: 476–482.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011; 117: 6063–6073.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L et al. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015; 21: 1155–1166.

    Article  PubMed  Google Scholar 

  5. Giralt S . 200 mg/m(2) melphalan-the gold standard for multiple myeloma. Nat Rev Clin Oncol 2010; 7: 490–491.

    Article  CAS  PubMed  Google Scholar 

  6. Martino M, Olivieri A, Offidani M, Vigna E, Moscato T, Fedele R et al. Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. Expert Opin Investig Drugs 2013; 22: 619–634.

    Article  CAS  PubMed  Google Scholar 

  7. Beaussant Y, Daguindau E, Pugin A, Mohty M, Avet-Loiseau H, Roos-Weil D et al. Hematopoietic stem cell transplantation in multiple myeloma: a retrospective study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Biol Blood Marrow Transplant 2015; 21: 1452–1459.

    Article  PubMed  Google Scholar 

  8. Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant 2015; 50: 209–215.

    Article  CAS  PubMed  Google Scholar 

  9. McCarthy PL Jr, Hahn T, Hassebroek A, Bredeson C, Gajewski J, Hale G et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transplant 2013; 19: 1116–1123.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Martino M, Montanari M, Bruno B, Console G, Irrera G, Messina G et al. Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program. Expert Opin Biol Ther 2012; 12: 1449–1462.

    Article  PubMed  Google Scholar 

  11. Summers N, Dawe U, Stewart DA . A comparison of inpatient and outpatient ASCT. Bone Marrow Transplant 2000; 26: 389–395.

    Article  CAS  PubMed  Google Scholar 

  12. Cantú-Rodríguez OG, Sánchez-Cárdenas M, Treviño-Montemayor OR, Gutiérrez-Aguirre CH, Tarín-Arzaga L, Jaime-Pérez JC et al. Impact of outpatient non-myeloablative haematopoietic stem cell transplantation in quality of life vs. conventional therapy. Psychol Health Med 2016; 21: 10–19.

    Article  PubMed  Google Scholar 

  13. Peters WP, Ross M, Vredenburgh JJ, Hussein A, Rubin P, Dukelow K et al. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 1994; 21 (4 Suppl 7): 25–31.

    CAS  PubMed  Google Scholar 

  14. Jagannath S, Vesole DH, Zhang M, Desikan KR, Copeland N, Jagannath M et al. Feasibility and cost effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant 1997; 20: 445–450.

    Article  CAS  PubMed  Google Scholar 

  15. Meisenberg BR, Ferran K, Hollenbach K, Brehm T, Jollon J, Piro LD . Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant 1998; 21: 927–932.

    Article  CAS  PubMed  Google Scholar 

  16. Morabito F, Martino M, Stelitano C, Oliva E, Kropp M, Irrera G et al. Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Haematologica 2002; 87: 1192–1199.

    PubMed  Google Scholar 

  17. Fernandez-Aviles F, Carreras E, Urbano-Ispizua A, Rovira M, Martínez C, Gaya A et al. Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies. J Clin Oncol 2006; 24: 4855–4861.

    Article  PubMed  Google Scholar 

  18. Kassar M, Medoff E, Seropian S, Cooper DL . Outpatient high-dose melphalan in multiple myeloma patients. Transfusion 2007; 47: 115–119.

    Article  CAS  PubMed  Google Scholar 

  19. Ferrara F, Izzo T, Criscuolo C, Riccardi C, Viola A, Delia R et al. Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis. Hematol Oncol 2011; 29: 139–143.

    Article  CAS  PubMed  Google Scholar 

  20. Gertz MA, Ansell SM, Dingli D, Dispenzieri A, Buadi FK, Elliott MA et al. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc 2008; 83: 1131–1138.

    Article  PubMed  Google Scholar 

  21. Faucher C, Le Corroller Soriano AG, Esterni B, Vey N, Stoppa AM, Chabannon C et al. Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs. Bone Marrow Transplant 2012; 47: 549–555.

    Article  CAS  PubMed  Google Scholar 

  22. Holbro A, Ahmad I, Cohen S, Roy J, Lachance S, Chagnon M et al. Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 547–551.

    Article  PubMed  Google Scholar 

  23. Scortechini I, Montanari M, Mancini G, Inglese E, Calandrelli M, Chiarucci M et al. Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma. Leuk Lymphoma 2014; 55: 1657–1660.

    Article  PubMed  Google Scholar 

  24. Paul TM, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ et al. Outpatient autologous stem cell transplantation for patients with myeloma. Clin Lymphoma Myeloma Leuk 2015; 15: 536–540.

    Article  PubMed  Google Scholar 

  25. Graff TM, Singavi AK, Schmidt W, Eastwood D, Drobyski WR, Horowitz M et al. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. Bone Marrow Transplant 2015; 50: 947–953.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Martino M, Montanari M, Ferrara F, Ciceri F, Scortechini I, Palmieri S et al. Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study. Biol Blood Marrow Transplant 2014; 20: 1026–1032.

    Article  PubMed  Google Scholar 

  27. Martino M, Russo L, Martinello T, Gallo GA, Fedele R, Moscato T et al. A home-care, early discharge model after autografting in multiple myeloma: results of a three-arm prospective, non-randomized study. Leuk Lymphoma 2015; 56: 801–804.

    Article  PubMed  Google Scholar 

  28. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1–12.

    Article  CAS  PubMed  Google Scholar 

  29. Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51–54.

    CAS  PubMed  Google Scholar 

  30. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248–1253.

    CAS  PubMed  Google Scholar 

  31. Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600–607.

    Article  CAS  PubMed  Google Scholar 

  32. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99—06): a randomized trial. Lancet 2007; 370: 1209–1218.

    Article  CAS  PubMed  Google Scholar 

  33. Kumar SK, Dingli D, Lacy MQ, Benboubker L, Attal M, Buadi FK et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol 2008; 83: 614–617.

    Article  PubMed  Google Scholar 

  34. Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M et al. Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood 2010; 115: 1873–1879.

    Article  CAS  PubMed  Google Scholar 

  35. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM et al. Feasibility of autologous hematopoietic stem cell transplant in patients aged >/=70 years with multiple myeloma. Leuk Lymphoma 2012; 53: 118–122.

    Article  CAS  PubMed  Google Scholar 

  36. Olivieri A, Marchetti M, Lemoli R, Tarella C, Iacone A, Lanza F et al. Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant 2012; 47: 342–351.

    Article  CAS  PubMed  Google Scholar 

  37. Olivieri A, Offidani M, Montanari M, Ciniero L, Cantori I, Ombrosi L et al. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Haematologica 1998; 83: 329–337.

    CAS  PubMed  Google Scholar 

  38. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C . Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360–1377.

    Article  CAS  PubMed  Google Scholar 

  39. Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37: 719–724.

    Article  CAS  PubMed  Google Scholar 

  40. Bensinger W, DiPersio JF, McCarty JM . Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009; 43: 181–195.

    Article  CAS  PubMed  Google Scholar 

  41. Sauter CS, Giralt S . The prognostic impact of peripheral blood progenitor cell dose following high-dose therapy and autologous stem cell transplant for hematologic malignancies. Leuk Lymphoma 2015; 56: 1619–1625.

    Article  CAS  PubMed  Google Scholar 

  42. Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2014; 20: 1262–1273.

    Article  PubMed  Google Scholar 

  43. Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant 2014; 20: 295–308.

    Article  PubMed  Google Scholar 

  44. Perseghin P, Marchetti M, Messina C, Mazzoni A, Carlier P, Perotti C et al. Best practice recommendations in: (1) Peripheral blood stem cell mobilization and collection and (2) acute and chronic GvHD treatment using extracorporeal photopheresis. A joint effort from SIdEM (Società Italiana di Emaferesi e Manipolazione Cellulare) and GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Transfus Apher Sci 2013; 48: 195–196.

    Article  CAS  PubMed  Google Scholar 

  45. Faussner F, Dempke WC . Multiple myeloma: myeloablative therapy with autologous stem cell support versus chemotherapy: a meta-analysis. Anticancer Res 2012; 32: 2103–2109.

    CAS  PubMed  Google Scholar 

  46. Armeson KE, Hill EG, Costa LJ . Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant 2013; 48: 562–567.

    Article  CAS  PubMed  Google Scholar 

  47. Kharfan-Dabaja MA, Hamadani M, Reljic T, Nishihori T, Bensinger W, Djulbegovic B et al. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol 2013; 6: 2.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075–2085.

    Article  CAS  PubMed  Google Scholar 

  49. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.

    Article  CAS  PubMed  Google Scholar 

  50. Tosi P, Zamagni E, Tacchetti P, Ceccolini M, Perrone G, Brioli A et al. Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. Biol Blood Marrow Transplant 2010; 16: 1115–1121.

    Article  CAS  PubMed  Google Scholar 

  51. Girmenia C, Rossolini GM, Piciocchi A, Bertaina A, Pisapia G, Pastore D et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant 2015; 50: 282–288.

    Article  CAS  PubMed  Google Scholar 

  52. Girmenia C, Viscoli C, Piciocchi A, Cudillo L, Botti S, Errico A et al. Management of carbapenem resistant klebsiella pneumoniae infections in stem cell transplant recipients: an italian multidisciplinary consensus statement. Haematologica 2015; 100: e373–e376.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Anastasia A, Giglio F, Mazza R, Sarina B, Todisco E, Bramanti S et al. Early discharge after high-dose melphalan and peripheral blood stem cell reinfusion in patients with hematological and non-hematological disease. Leuk Lymphoma 2009; 50: 80–84.

    Article  CAS  PubMed  Google Scholar 

  54. Center for International Blood and Marrow Transplant Research (CIBMTR), National Marrow Donor Program (NMDP), European Blood and Marrow Transplant Group (EBMT), American Society of Blood and Marrow Transplantation (ASBMT), Canadian Blood and Marrow Transplant Group (CBMTG), Infectious Disease Society of America (IDSA) et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant 2009; 44: 453–558.

    Article  Google Scholar 

  55. Weissinger F, Auner HW, Bertz H, Buchheidt D, Cornely OA, Egerer G et al. Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2012; 91: 1161–1174.

    Article  PubMed  Google Scholar 

  56. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT, American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 215–219.

    Article  CAS  PubMed  Google Scholar 

  57. Bock AM, Cao Q, Ferrieri P, Young JA, Weisdorf DJ . Bacteremia in blood or marrow transplantation patients: clinical risk factors for infection and emerging antibiotic resistance. Biol Blood Marrow Transplant 2013; 19: 102–108.

    Article  PubMed  Google Scholar 

  58. Piñana JL, Montesinos P, Martino R, Vazquez L, Rovira M, Lopez J et al. Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. Ann Hematol 2014; 93: 299–307.

    Article  PubMed  Google Scholar 

  59. Satlin MJ, Vardhana S, Soave R, Shore TB, Mark TM, Jacobs SE et al. Impact of prophylactic levofloxacin on rates of bloodstream infection and fever in neutropenic patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2015; 21: 1808–1814.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Pagano L, Caira M . The role of primary antifungal prophylaxis in patients with haematological malignancies. Clin Microbiol Infect 2014; 20 (Suppl 6): 19–26.

    Article  CAS  PubMed  Google Scholar 

  61. Kontoyiannis DP, Patterson TF . Diagnosis and treatment of invasive fungal infections in the cancer patient: recent progress and ongoing questions. Clin Infect Dis 2014; 59: S356–S359.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31: 794–810.

    Article  PubMed  Google Scholar 

  63. Blijlevens N, de Château M, Krivan G, Rabitsch W, Szomor A, Pytlik R et al. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden. Bone Marrow Transplant 2013; 48: 966–971.

    Article  CAS  PubMed  Google Scholar 

  64. Tsirigotis P, Triantafyllou K, Girkas K, Giannopoulou V, Ioannidou E, Chondropoulos S et al. Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study. Bone Marrow Transplant 2008; 42: 337–343.

    Article  CAS  PubMed  Google Scholar 

  65. Kobbe G, Bruns I, Schroeder T, Czibere A, Warnecke J, Hieronimus N et al. A 3- day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. Ann Oncol 2010; 21: 1898–1904.

    Article  CAS  PubMed  Google Scholar 

  66. Milone G, Leotta S, Cupri A, Fauci AL, Spina P, Parisi M et al. Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa. Bone Marrow Transplant 2014; 49: 1193–1197.

    Article  CAS  PubMed  Google Scholar 

  67. Worthington HV, Clarkson JE, Bryan G, Furness S, Glenny AM, Littlewood A et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2011; (4): CD000978.

  68. Bassi S, Stroppa EM, Moroni CF, Arbasi MC, Trabacchi E, Di Franco A et al. Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens. Blood Transfus 2015; 13: 478–483.

    PubMed  PubMed Central  Google Scholar 

  69. Martino M, Recchia AG, Moscato T, Fedele R, Neri S, Gentile M et al. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients. Cytotherapy 2015; 17: 1485–1493.

    Article  CAS  PubMed  Google Scholar 

  70. Martino M, Praticò G, Messina G, Irrera G, Massara E, Messina G et al. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol 2006; 77: 410–415.

    Article  CAS  PubMed  Google Scholar 

  71. Ziakas PD, Kourbeti IS . Pegfilgrastim vs. filgrastim for supportive care after autologous stem cell transplantation: can we decide? Clin Transplant 2012; 26: 16–22.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. M Montanari

    Present address: Department of Pediatric Hematology/Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Pediatrico Bambino Gesù, Rome, Italy.,

Authors and Affiliations

  1. Dipartimento di Onco-Ematologia, Ematologia con Trapianto di Midollo Osseo, Azienda Ospedaliera BMM, Reggio Calabria, Italy

    M Martino

  2. Dipartimento di Medicina Interna e Specialità Mediche, Cattedra di Ematologia, Università di Genova, Genova, Italy

    R M Lemoli

  3. Dipartimento di Biotecnologie Cellulari ed Ematologia, Policlinico Umberto I, “Università la Sapienza”, Roma, Italy

    C Girmenia

  4. Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano (MI), Italy

    L Castagna

  5. Division of Hematology, and Department of Molecular Biotechnology and Health Sciences, A.O.U. Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy

    B Bruno & F Cavallo

  6. Clinica di Ematologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, Italy

    M Offidani, I Scortechini, M Montanari & A Olivieri

  7. Dipartimento di Ematologia, Unità Trapianto di Midollo Osseo, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy

    G Milone

  8. Clinica Medica Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, Italy

    L Postacchini

Authors
  1. M Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R M Lemoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Girmenia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Bruno
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F Cavallo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Offidani
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I Scortechini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Montanari
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G Milone
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. L Postacchini
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A Olivieri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to M Martino or A Olivieri.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Author contributions

Each member of the panel was assigned a specific topic and proposed recommendations during the meetings. All authors discussed the final version in a plenary session. MMa, RML and AO drafted the final report which was, in turn, reviewed and approved by the whole panel.

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Martino, M., Lemoli, R., Girmenia, C. et al. Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. Bone Marrow Transplant 51, 1032–1040 (2016). https://doi.org/10.1038/bmt.2016.79

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.79

This article is cited by

Search

Advanced search

Quick links